KCM
FHTX icon

Kingdon Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Kingdon Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-54,241
Closed -$826K – 80
2022
Q1 		$826K Sell
54,241
-100
-0.2% -$1.37K 0.09% 76
2021
Q4 		$1.24M Sell
54,341
-151,400
-74% -$2.18M 0.14% 72
2021
Q3 		$2.87M Buy
+205,741
New +$2.28M 0.35% 49

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Kingdon Capital Management's FHTX Position: Q2 2022 in Review

Kingdon Capital Management sold out of Foghorn Therapeutics (FHTX) in Q2 2022, closing a stake of 54,241 shares — an estimated $826K sold.

Kingdon Capital Management first reported a position in FHTX in Q3 2021 and held it in 3 quarters. The position peaked at $2.87M in Q3 2021. 60 funds tracked by Wall St. Rank hold FHTX as of Q2 2022.

  • Kingdon Capital Management reported no remaining Foghorn Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kingdon Capital Management sold 54,241 Foghorn Therapeutics shares in Q2 2022, an estimated $826K.
  • Kingdon Capital Management first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 3 quarters.
  • Kingdon Capital Management's Foghorn Therapeutics position peaked at $2.87M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2022.

Based on Kingdon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.